1. 疾病领域
  2. 炎症和免疫系统疾病 消化系统疾病
  3. 消化道统炎症
  4. 非酒精性脂肪性肝炎

Nonalcoholic Steatohepatitis  (非酒精性脂肪性肝炎)

非酒精性脂肪性肝炎 (NASH) 是一种严重的非酒精性脂肪性肝病 (NAFLD),其特征是肝脏脂肪堆积、炎症和肝细胞损伤,且无大量饮酒史。NASH 代表着肝脏从单纯脂肪变性进展为炎症和纤维化改变,并可能导致肝硬化、肝衰竭或肝细胞癌。脂肪性肝炎的实验模型用于研究其病理生理机制,并评估针对脂质代谢和肝脏组织学的治疗干预措施。

Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD) characterized by hepatic fat accumulation, inflammation, and hepatocellular injury, without significant alcohol consumption. It represents a progression from simple steatosis to inflammatory and fibrotic changes in the liver, with potential to lead to cirrhosis, liver failure, or hepatocellular carcinoma. Experimental models of steatohepatitis are used to investigate pathophysiological mechanisms and evaluate therapeutic interventions targeting lipid metabolism and liver histology.

Nonalcoholic Steatohepatitis (1):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0385
    Gomisin J

    戈米辛J

    66280-25-9 99.97%
    Gomisin J 是一五味子来源的木脂素,可靶向 eNOSAMPK (LKB1CaMKIIβ)、fetuin-ANF-κBNrf2/HO-1 等多个靶点,且能通过血脑屏障。Gomisin J 通过激活 eNOS 增加 NO 生物利用度、激活 AMPK 通路调节脂代谢、抑制 fetuin-A 和 NF-κB 发挥抗炎作用、激活 Nrf2/HO-1 增强抗氧化能力等机制。Gomisin J 具有抗高血压、调节肝脂代谢、减轻脑缺血再灌注损伤等活性,可用于高血压、非酒精性脂肪肝、脑缺血再灌注损伤等研究。
    Gomisin J